MaxVal Blog

    Filter by Category
    Filter by Category

    Go Back to Homepage

    Hot Topics in Tech | June 2018 Newsletter | Maxval

    Hot Topics June

    In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA's approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.

    We have also discussed Microsoft's Azure Internet of Things (IoT) Edge and its key features. A quick look at the patent filings claiming Edge or Fog computing revealed Intel has the most number of filings in this space. Read more on this report.

    Go Back to Homepage

    Technology Landscape Study on CRISPR-Cas9
    Hot Topics in Tech | August 2018 Newsletter | Maxval

    About Author

    MaxVal
    MaxVal

    Related Posts
    Serving Up Patents for Thanksgiving Dinner
    Serving Up Patents for Thanksgiving Dinner
    Hot Topics in Tech | October 2019 Newsletter
    Hot Topics in Tech | October 2019 Newsletter
    Hot Topics in Tech | September 2019 Newsletter
    Hot Topics in Tech | September 2019 Newsletter

    Comment

    Subscribe To Blog

    Subscribe to Email Updates